Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients

Authors: Sheikh Omar Bittaye, Abubacarr Kambi, Momodou A. I. Tekanyi, Saydiba Tamba, Lamin Sanneh, Momodou Musa Sisawo, Abdoulie Jatta, Gibril Fatty, Adam Jeng, Momodou Salieu Jallow, Ousman Leigh, Ramou Njie

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

As a result of the lack of screening programs and the difficulty in making a proper diagnosis, the majority of hepatocellular carcinoma (HHC) patients present late in low-resource countries. The study therefore assesses the clinical features, stage and prognostic variables of patients with HCC in The Gambia.

Methods

From December 2015 to January 2019, patients with a confirmed diagnosis of HCC were enrolled. All patients’ medical history, ultrasound scan, FibroScan and laboratory details were collected.

Results

Two hundred and sixty (260) patients were enrolled. The mean age of HCC patients was 40 years, and 210 (80.7%) of them were male. The most common gastrointestinal symptoms were early satiety 229 (88.1%) and abdominal pain 288 (87.7%), while the most common constitutional symptoms were weight loss 237 (91.2%) and easy fatiguability 237 (91.2%). Hepatomegaly 205 (78.8%) was the most common sign. On ultrasound scan, lesions were mostly multifocal 175 (67.3%), and the median FibroScan score was 75 kPa. The median fibrosis 4 and aspartate transferase platelet ratio index were 4.6 and 2.2, respectively. Hepatitis B surface antigen (HBsAg) was positive in 170 (65.4%) patients, and the median AFP level was 3263 ng/ml. HCC patients with positive HBsAg were more likely to be male 145 (85.3%) vs 62 (72.1%) (p = 0.011), much younger 39.9 vs 51.4 yrs (p =  < 0.0001), more likely to have abdominal pain 156 (91.8%) vs 68 (79.1%) (p = 0.002), jaundice 78 (45.9%) vs 29 (33.7%) (p = 0.042), dark urine 117 (68.8%) vs 46 (53.5%) (p = 0.018), raised transaminases (Aspartate transaminases 224.5 (32–7886) vs 153 (18–610), p =  < 0.01, Alanine transferases 71 (5–937) vs 47 (8–271), p =  < 0.001) and decreased platelet count 207 (33–941) vs 252 (52- 641) (p = 0.021) compared to patients with HCC who were HBsAg-negative.

Conclusions

The prognosis of patients with HCC is poor in developing countries such as The Gambia, where screening programs and treatment modalities are scarce. Young males are disproportionately affected, and HBV is a major cause of HCC in The Gambia.
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA A Cancer J Clin. 2021;71:209–49.CrossRef
2.
go back to reference Mukthinuthalapati VVPK, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, et al. Hepatocellular carcinoma in Sub-Saharan Africa. JCO Global Oncol. 2021;7:756–66.CrossRef Mukthinuthalapati VVPK, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, et al. Hepatocellular carcinoma in Sub-Saharan Africa. JCO Global Oncol. 2021;7:756–66.CrossRef
3.
go back to reference Yang JD, Lewis RR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2014;24:899.CrossRef Yang JD, Lewis RR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2014;24:899.CrossRef
4.
go back to reference Amponsah-dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27:6025–38.CrossRefPubMedPubMedCentral Amponsah-dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030? World J Gastroenterol. 2021;27:6025–38.CrossRefPubMedPubMedCentral
5.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer. 2008;127:2893–917.CrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer. 2008;127:2893–917.CrossRef
6.
go back to reference Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, et al. Problem of hepatocellular carcinoma in West Africa. World J HepatoL. 2014;6:783–92.CrossRefPubMedPubMedCentral Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, et al. Problem of hepatocellular carcinoma in West Africa. World J HepatoL. 2014;6:783–92.CrossRefPubMedPubMedCentral
7.
go back to reference Jaquet A, Tchounga B, Tanon A, Bagny A, Didier K, Traore HA, et al. Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer. 2018;143(4):869–77.CrossRefPubMedPubMedCentral Jaquet A, Tchounga B, Tanon A, Bagny A, Didier K, Traore HA, et al. Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer. 2018;143(4):869–77.CrossRefPubMedPubMedCentral
9.
go back to reference Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed
10.
go back to reference Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia : the Prevention of Liver Fibrosis and Cancer in Africa ( PROLIFICA ) study. Lancet Glob Heal. 2011;4:e559–67.CrossRef Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia : the Prevention of Liver Fibrosis and Cancer in Africa ( PROLIFICA ) study. Lancet Glob Heal. 2011;4:e559–67.CrossRef
11.
go back to reference Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573–83.CrossRefPubMed Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther. 2006;24:573–83.CrossRefPubMed
13.
go back to reference Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 Years into the Gambia hepatitis intervention study : assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3216–24.CrossRefPubMed Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, et al. 20 Years into the Gambia hepatitis intervention study : assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:3216–24.CrossRefPubMed
14.
go back to reference Bah E, Carrieri MP, Hainaut P, Bah Y, Nyan O, Taal M. 20-years of population-based cancer registration in hepatitis b and liver cancer prevention in The Gambia. West Africa PLoS One. 2013;8:1–11. Bah E, Carrieri MP, Hainaut P, Bah Y, Nyan O, Taal M. 20-years of population-based cancer registration in hepatitis b and liver cancer prevention in The Gambia. West Africa PLoS One. 2013;8:1–11.
15.
go back to reference Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39:211–9.CrossRefPubMed Kirk G, Lesi O, Mendy M, Akano A, Sam O, Goedert J, et al. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004;39:211–9.CrossRefPubMed
16.
go back to reference Manieri E, Herrera-melle L, Mora A, Tom A, Leiva-vega L, Fern DI, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216:1108–19.CrossRefPubMedPubMedCentral Manieri E, Herrera-melle L, Mora A, Tom A, Leiva-vega L, Fern DI, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216:1108–19.CrossRefPubMedPubMedCentral
17.
go back to reference Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:575–84.CrossRefPubMed Zheng B, Zhu YJ, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:575–84.CrossRefPubMed
18.
go back to reference Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int. 2011;31:215–21.CrossRefPubMed Umoh NJ, Lesi OA, Mendy M, Bah E, Akano A, Whittle H, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int. 2011;31:215–21.CrossRefPubMed
19.
go back to reference Mboto CI, Russell AD, Fielder M, Jewell AP. Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C. Int Semin Surg Oncol. 2005;2:1–5.CrossRef Mboto CI, Russell AD, Fielder M, Jewell AP. Hepatocellular Carcinoma in The Gambia and the role of Hepatitis B and Hepatitis C. Int Semin Surg Oncol. 2005;2:1–5.CrossRef
20.
go back to reference Diallo I, Ndiaye B, Touré M, Sow A, Mbengue A, Diawara PS, et al. Hepatocellular carcinoma in senegal : epidemiological, clinical and etiological aspects about 229 cases at Hôpital Principal de Dakar. Pan Afr Med J. 2021;38:99.CrossRefPubMedPubMedCentral Diallo I, Ndiaye B, Touré M, Sow A, Mbengue A, Diawara PS, et al. Hepatocellular carcinoma in senegal : epidemiological, clinical and etiological aspects about 229 cases at Hôpital Principal de Dakar. Pan Afr Med J. 2021;38:99.CrossRefPubMedPubMedCentral
21.
22.
go back to reference Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, et al. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLoS ONE. 2023;18:1–13.CrossRef Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, et al. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLoS ONE. 2023;18:1–13.CrossRef
23.
go back to reference Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37–49.CrossRefPubMed Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37–49.CrossRefPubMed
24.
go back to reference Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMed Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMed
25.
go back to reference Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia hepatitis intervention study (1986–90) and in the nationwide immunisation program. BMC Infect Dis. 2014;14:1–8.CrossRef Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia hepatitis intervention study (1986–90) and in the nationwide immunisation program. BMC Infect Dis. 2014;14:1–8.CrossRef
26.
go back to reference Whittle HC, Inskip HI, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet Glob Heal. 1991;337:747–50. Whittle HC, Inskip HI, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet Glob Heal. 1991;337:747–50.
27.
go back to reference Mendy M, Peterson I, Hossin S, Peto T, Jobarteh M, Whittle H, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis b vaccination in two Gambian villages : no need for a booster dose. PLoS. 2013;8:E58029.CrossRef Mendy M, Peterson I, Hossin S, Peto T, Jobarteh M, Whittle H, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis b vaccination in two Gambian villages : no need for a booster dose. PLoS. 2013;8:E58029.CrossRef
28.
go back to reference Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia : protection against carriage at 9 years of age. Vaccine. 1999;17:2946–50.CrossRefPubMed Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia : protection against carriage at 9 years of age. Vaccine. 1999;17:2946–50.CrossRefPubMed
29.
go back to reference Zhang L, Lv Y, Xu A, Wang H. The prognostic significance of serum gamma-glutamyltransferase levels and AST / ALT in primary hepatic carcinoma. BMC Cancer. 2019;19:841.CrossRefPubMedPubMedCentral Zhang L, Lv Y, Xu A, Wang H. The prognostic significance of serum gamma-glutamyltransferase levels and AST / ALT in primary hepatic carcinoma. BMC Cancer. 2019;19:841.CrossRefPubMedPubMedCentral
30.
go back to reference Schrecker C, Waidmann O, El YH, Trojan J, Schnitzbauer AA, Bechstein WO, et al. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma. Curr Oncol. 2022;29:1475–87.CrossRefPubMedPubMedCentral Schrecker C, Waidmann O, El YH, Trojan J, Schnitzbauer AA, Bechstein WO, et al. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma. Curr Oncol. 2022;29:1475–87.CrossRefPubMedPubMedCentral
31.
go back to reference Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97:e13696.CrossRefPubMed Zhang Y, Wang R, Yang X. FIB-4 index serves as a noninvasive prognostic biomarker in patients with hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2018;97:e13696.CrossRefPubMed
32.
go back to reference Allenson K, Roife D, Kao LS, Ko TC, Wray CJ. Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index. J Gastrointest Oncol. 2020;11:291–7.CrossRefPubMedPubMedCentral Allenson K, Roife D, Kao LS, Ko TC, Wray CJ. Estimation of hepatocellular carcinoma mortality using aspartate aminotransferase to platelet ratio index. J Gastrointest Oncol. 2020;11:291–7.CrossRefPubMedPubMedCentral
33.
go back to reference Zhang XY, Svn Z, Liv MS, Liu MN, Zhang YH, Sun Q. Assessment of prognostic value of aspartate aminotransferase-to-platelet ratio index in patients with hepatocellular carcinoma: meta-analysis of 28 cohort studies. Front Med. 2021;8:756210.CrossRef Zhang XY, Svn Z, Liv MS, Liu MN, Zhang YH, Sun Q. Assessment of prognostic value of aspartate aminotransferase-to-platelet ratio index in patients with hepatocellular carcinoma: meta-analysis of 28 cohort studies. Front Med. 2021;8:756210.CrossRef
34.
go back to reference Koji U, Ryosuke T, Shuichiro S, Miho K, Ryota M, et al. Hepatocellular carcinoma with extrahepatic metastasis. Cancer. 2011;117:4475–83.CrossRef Koji U, Ryosuke T, Shuichiro S, Miho K, Ryota M, et al. Hepatocellular carcinoma with extrahepatic metastasis. Cancer. 2011;117:4475–83.CrossRef
35.
go back to reference Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, et al. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol. 2018;10:51–61.CrossRefPubMedPubMedCentral Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, et al. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol. 2018;10:51–61.CrossRefPubMedPubMedCentral
36.
go back to reference Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13:414–20.CrossRefPubMedPubMedCentral Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13:414–20.CrossRefPubMedPubMedCentral
37.
go back to reference Yang JD, Mohamed EA, Abdelaziz AO, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics , management , and outcomes of patients with hepatocellular carcinoma in Africa : a multicountry observational study from the Africa Liver Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRefPubMed Yang JD, Mohamed EA, Abdelaziz AO, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics , management , and outcomes of patients with hepatocellular carcinoma in Africa : a multicountry observational study from the Africa Liver Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRefPubMed
38.
go back to reference Seid AS, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD, et al. Single center analysis of therapy and outcomes of Hepatocellular carcinoma in Sub-Saharan Africa: an Ethiopian experience. Expert Rev Gastroenterol Hepatol. 2020;14:1007–11.CrossRefPubMedCentral Seid AS, Anugwom CM, Wondifraw Z, Braimoh GA, Bane A, Debes JD, et al. Single center analysis of therapy and outcomes of Hepatocellular carcinoma in Sub-Saharan Africa: an Ethiopian experience. Expert Rev Gastroenterol Hepatol. 2020;14:1007–11.CrossRefPubMedCentral
Metadata
Title
Clinical manifestation, staging and prognosis of hepatocellular carcinoma in Gambian patients
Authors
Sheikh Omar Bittaye
Abubacarr Kambi
Momodou A. I. Tekanyi
Saydiba Tamba
Lamin Sanneh
Momodou Musa Sisawo
Abdoulie Jatta
Gibril Fatty
Adam Jeng
Momodou Salieu Jallow
Ousman Leigh
Ramou Njie
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02952-8

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.